Hi, what are you looking for?
Teva declined the chance because it does not operate in the store-brand OTC market, Perrigo's main activity.
Reuters Exclusive: Generics drugmaker Mylan NV (MYL.O), which is in the middle of a three-way takeover battle, has said it is unwilling to...
John Paulson's hedge fund has increased its holdings in Mylan NV to 4.5%.
The Teva shareholder and digital printing pioneer thinks Teva should be investing in innovation, not cheap commodity drugs.
[FULL LETTER] After Mylan Responded aggressively to Teva's bid, Erez Vigodman says in an open letter to Robert Coury: Shareholders won't benefit from Mud...
Julius Baer analyst Lilian Montero insists it's illogical for Mylan to remain independent.
Tamir Capital is invested in Proneuron, which successfully sued Teva for abuse of a license for its product.
Board concludes that approach grossly undervalues Mylan, includes Teva stock, and would expose Mylan to a problematic culture and leadership with poor record of...
Teva CEO Erez Vigodman bypasses Mylan's board and appeals directly to its shareholders.
Generic drugmaker Mylan (MYL) said on Friday it would take its $31 billion offer for Perrigo Co Plc directly to shareholders, in what is...